Black­stone bags Clarus, stak­ing out a grow­ing PhI­II niche for it­self in a rapid­ly chang­ing bio­phar­ma in­dus­try

Black­stone likes life sci­ences. And now it’s div­ing in deep.

The pri­vate eq­ui­ty gi­ant has com­plet­ed a deal to buy Clarus, a busy life sci­ences in­vestor with an ex­ten­sive his­to­ry of gam­bling on late-stage drug de­vel­op­ment. 

With $2.6 bil­lion un­der man­age­ment, Clarus is a peanut on Black­stone’s $440 bil­lion plate. But with $19 bil­lion in health­care deals com­plet­ed and a vast port­fo­lio of biotech fa­cil­i­ty space on its books, Black­stone has the re­sources to go much big­ger in a field that has been ex­plod­ing with new ac­tiv­i­ty over the last few years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER